In advanced lymphoma cases, subsequent to a low-dose chemotherapy induction employing cyclophosphamide and fludarabine, CD19 CAR-T therapy administered after a 48-h interval led to an overall patient response rate of 73%. The gene discussed is CD19; the disease is lymphoma.